Navy’s highest-ranking officer successfully treated for breast cancer
Chief of Naval Operations Adm. Lisa Franchetti was treated successfully for early-stage breast cancer this summer, the ...
MM&M7h
Daiichi Sankyo launches first DTC ad for Enhertu, representing shift toward patient-centric oncology campaigns
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
The Navy's highest-ranking military officer is treated successfully for breast cancer
The Navy says its highest-ranking military officer has been successfully treated for early-stage breast cancer ...
FiercePharma12h
Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
oncnursingnews12h
ESR1 Testing Is Crucial in Second-line HR+, HER2- Metastatic Breast Cancer
During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...
News Medical22h
Anti-fibrotic drug shows promise in breast cancer
The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of ...